Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies

Abstract

The persistence and reactivity of CAR T cells were enhanced by adding co-stimulatory domains, which is the basis of currently approved CAR-T cell therapies. However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti-CD19 CAR-T cell therapy with a single activation domain to show a favourable safety profile and clinical efficacy with two patients who achieved durable responses up to 28 months in a cohort with heavily pretreated B cell malignancies.

Keywords: B cell malignancies; CAR‐T cell therapy; Phase I trial; first‐generation.